公开(公告)号：EP1563301A4

公开(公告)日：2007-07-11

申请号：EP03789967

申请日：2003-11-20

申请人： SANARIA INC

发明人： HOFFMAN STEPHEN L ,  LUKE THOMAS C

IPC分类号： A61K20060101 ,  A61K39/00 ,  A61K39/002 ,  A61K39/015 ,  G01N33/536

CPC分类号： A61K39/015 ,  A61K2039/515

摘要： The invention comprises a novel method for protecting subjects against malaria. The method of the invention involves inoculation with attenuated sporozoites, and in particular, but not limited to subcutaneous, intramuscular, intradermal, mucosal, submucosal, and cutaneous administration.

公开(公告)号：EP3039421A4

公开(公告)日：2017-04-05

申请号：EP14839238

申请日：2014-09-02

申请人： SANARIA INC ,  ANTIGEN DISCOVERY INC ,  THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES

发明人： FELGNER PHILIP ,  HOFFMAN STEPHEN L ,  SEDER ROBERT

IPC分类号： A61K39/015 ,  G01N33/68

CPC分类号： G01N33/6854 ,  A61K39/015 ,  G01N2333/445 ,  G01N2469/20

摘要： Disclosed herein are diagnostic assays for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such assays are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. The assays comprise the use of proteomes representing at least 50% of Pf, preferably coupled to a solid phase as a fixed array. The arrays are used to probe the sera of human subjects, particularly subjects of human clinical trials of whole parasite malaria vaccines as well as public health vaccination campaigns. Serum samples with antibody profiles most strongly reactive in multiplex to CSP and MSP5 demonstrate a sensitivity of from 92% to 100% and a specificity of from 84% to 89%.

公开(公告)号：EP2387416A4

公开(公告)日：2012-09-12

申请号：EP10731974

申请日：2010-01-08

申请人： SANARIA INC

发明人： SIM B KIM LEE ,  LI MINGLIN ,  STAFFORD RICHARD E ,  HOFFMAN STEPHEN L

IPC分类号： A61K39/015

CPC分类号： A61K39/015 ,  A61K9/0019 ,  A61K31/4706 ,  A61K2039/522 ,  A61K2039/6081

摘要： Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.

摘要翻译： 公开了基本上纯化的疟原虫子孢子和与附带的非子孢子物质基本分离的疟原虫子孢子的制剂，其中疟原虫子孢子的制剂具有增加的纯度水平。 同样提供包含纯化的疟原虫子孢子的疫苗和药物组合物。 还提供了提纯疟原虫子孢子的制备方法。

公开(公告)号：EP1492402A4

公开(公告)日：2005-06-22

申请号：EP03718272

申请日：2003-04-07

申请人： SANARIA INC

发明人： HOFFMAN STEPHEN L ,  LUKE THOMAS C

IPC分类号： A01K67/00 ,  A01K67/033 ,  A61B17/20 ,  A61K39/015 ,  A61P33/06 ,  A01K29/00 ,  A01M1/20 ,  C12N15/00

CPC分类号： A01K67/033

公开(公告)号：EP3137106A4

公开(公告)日：2018-01-17

申请号：EP15786133

申请日：2015-05-01

申请人： SANARIA INC

发明人： EAPPEN ABRAHAM G ,  HOFFMAN STEPHEN L

IPC分类号： A61K39/015 ,  C12N1/10

CPC分类号： A61K39/015 ,  A61K2039/52 ,  A61K2039/522 ,  C12N1/10

摘要： The application is directed to in-vitro-reared Plasmodium sporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectious Plasmodium sporozoites (SPZ) of human host range, particularly P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same.